Science Policy news weekly update: August 14, 2017 ?>

Science Policy news weekly update: August 14, 2017


What’s new in Blotter news?

The ASBMB has been providing feedback to the National Institutes of Health regarding its Next Generation Researchers Initiative.

The ASBMB provides feedback regarding the NIH’s Next Generation Researchers Initiative


Science Policy Analyst Andre Porter discusses the White House memo with its priorities for research and development to guide federal funding.

President Trump releases his research and development priorities for FY19


A recent National Academies of Science report stated that the American biomedical research industry is not well-prepared for disasters like cyberattacks or hurricanes. After damages to infrastructure, equipment and data from Hurricanes Katrina and Sandy, no steps were taken to prevent future storms from inflicting harm. The report also lists recommendations for the community to mitigate damage from disasters.

U.S. academic biomedical labs said unready for disasters (ACS)


A recent study is the latest to suggest that many animal biomedical experiments fail to take into account the differences in sexes. Researchers showed that more than half of quantifiable traits, such as height and metabolism, were different between male and female mice. Furthermore, single gene mutations resulted in more than 15 percent of quantifiable traits showing sexual dimorphism. This study highlights the perils of drug development using research based on a single sex.

A major blind spot in animal testing is endangering the lives of women (Quartz)


The Discovery Channel is airing a documentary, called “First in Human,” detailing the involvement of individuals in clinical trials at the NIH. The documentary highlights the importance of these clinical trial in the development of treatments and therapies for many conditions. The documentary aims to fight misconceptions about participating in clinical trials.


Discovery’s ‘First In Human’ calls much-needed attention to clinical trials (Forbes)


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.